Vol.74 No.6 November 2026
Trends in the prescription of oral antiviral drugs for COVID-19 and clinical outcomes: a single-center experience
1)Office of Infection Control and Prevention, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
Abstract
In the outpatient management of patients at high risk for severe COVID-19, both domestic and international guidelines recommend nirmatrelvir/ritonavir (NMV/r) as first-line antiviral therapy. In accordance with this recommendation, our institution has prioritized the use of this antiviral drug combination through multidisciplinary collaboration. However, as of September 15, 2022, molnupiravir (MOV) accounted for over 90% of all domestic oral antiviral drug prescriptions among patients with COVID-19. Data on the prescribing patterns for treating COVID-19 in patients with cancer in Japan are limited. Therefore, we conducted a study to evaluate the prescribing trends and efficacy of each drug at our institution with the aim of informing future antiviral prescribing practices. Among 92 consecutive patients with cancer who were prescribed antiviral drugs between January 2022 and October 2023, NMV/r and MOV were prescribed to 54 (58.7%) and 38 (41.3%) patients, respectively. No COVID-19-related hospitalizations were reported within 4 weeks of prescription in the NMV/r group whereas two hospitalizations were recorded in the MOV group, with no significant difference between the two groups. No deaths were reported within 4 weeks of prescription in either group. These findings suggest that NMV/r can be prescribed through multidisciplinary collaboration, even in specialized cancer centers.
Key word
COVID-19, nirmatrelvir/ritonavir, molnupiravir, outcome, cancer patient
Received
April 27, 2026
Accepted
July 9, 2026
Jpn. J. Chemother. 74 (6): 792-796, 2026


